Korean J Helicobacter Up Gastrointest Res > Volume 22(3); 2022 > Article |
|
Medical care benefit criteria |
Korean College of Helicobacter and Upper Gastrointestinal Research guideline recommendations |
|||
---|---|---|---|---|
Year | Level of evidence | Strength of recommendation | ||
Permitted | ||||
Peptic ulcer disease | 2013 | High | Strong | |
Primary gastric marginal zone B-cell lymphoma | 2013 | High | Strong | |
After resection of early gastric cancer | 2013b | High | Strong | |
Idiopathic thrombocytopenic purpura | 2013 | High | Strong | |
After endoscopic resection of gastric adenoma | 2020 | Low | Weak | |
Exceeding the permitteda | ||||
First-degree relatives with a family history of gastric cancer | 2013 | Moderate | Weak | |
Atrophic gastritis | 2020 | - | Not recommended, but considered as an admissive indication | |
In cases that patients consent to H. pylori treatment because it is required for other medical conditions | Other medical conditions might include as follows: | |||
Functional dyspepsia (2020) | High | Weak | ||
Iron deficiency anemia (2020) | Very low | Weak | ||
Long-term low-dose aspirin user with a history of peptic ulcer (2013) | Low | Weak | ||
H. pylori negative-marginal zone B-cell lymphoma | No recommendation | - | - |
Medicationsa | Medical care benefitb | |
---|---|---|
Proton pump inhibitors | • Omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole | |
- Approved for all permitted indications of treatment | ||
- Approved in exceeding the permitted indication of H. pylori treatment, but patients should pay 100% of the cost | ||
• Ilaprazole | ||
- Approved only for peptic ulcer disease | ||
Antibiotics | • Amoxicillin, clarithromycin, metronidazole, tetracycline | |
- Approved for all permitted indications of H. pylori treatment | ||
- Approved in exceeding the permitted indication of H. pylori treatment, but patients should pay 100% of the cost | ||
• Levofloxacin | ||
- Approved only used in the 3rd line H. pylori treatment (10~14 days) | ||
Bismuth | • Approved for all permitted indications of H. pylori treatment | |
• Approved in exceeding the permitted indication of H. pylori treatment, but patients should pay 100% of the cost |
Diagnostic test | Medical care benefit | The Ministry of Health and Welfare Notification No. (start date) | |
---|---|---|---|
H. pylori test (rapid urease test, histology, serology, stool antigen test) | • Approved in the permitted indication of H. pylori treatmenta | No. 2018-80 (2018.05.01) | |
• Approved in exceeding the permitted indication of H. pylori treatment, but patients should pay 90% of the cost | |||
Clarithromycin-resistance test (PCR or NGS) | • Approved only once in the permitted indication of H. pylori treatmenta | No. 2021-177 (2021.07.01) | |
• Approved in exceeding the permitted indication of H. pylori treatment, but patients should pay 80% of the cost | |||
※ For the NGS test, patients should pay 80% of the cost. | |||
※ In cases when both PCR and NGS tests are performed, only one of them is approved. | |||
Urea breath test | • Approved as a test confirming H. pylori infection status after treatment | No. 2017-263 (2018.01.01) | |
- Regardless of the H. pylori treatment indication, the test is approved. | |||
• Approved as a diagnostic test of H. pylori infection status in the following cases | |||
- In patients at high risk of bleeding who have an endoscopy-confirmed peptic ulcerb | |||
- Idiopathic thrombocytopenic purpura |
Evidence-based Therapy: A Rational Approach to Helicobacter pylori Eradication2023 June;23(2)
Bismuth, An Indispensable Component of Helicobacter pylori Eradication Therapy2023 June;23(2)
Antimicrobial Resistance of Helicobacter pylori Isolates in Korea2019 March;19(1)
Molecular Pathogenic Mechanism of Helicobacter pylori Infection2002 November;2(2)